Jorma Hinkula
Jorma Hinkula
Professor i molekylär virologi, Linköpings universitet
Verified email at
Cited by
Cited by
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
S Calarota, G Bratt, S Nordlund, J Hinkula, AC Leandersson, E Sandström, ...
The Lancet 351 (9112), 1320-1325, 1998
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells
C Devito, K Broliden, R Kaul, L Svensson, K Johansen, P Kiama, J Kimani, ...
The Journal of Immunology 165 (9), 5170-5176, 2000
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate
C Devito, J Hinkula, R Kaul, L Lopalco, JJ Bwayo, F Plummer, M Clerici, ...
Aids 14 (13), 1917-1920, 2000
Experimental autoimmune encephalomyelitis in NF-κB-deficient mice: roles of NF-κB in the activation and differentiation of autoreactive T cells
B Hilliard, EB Samoilova, TST Liu, A Rostami, Y Chen
The Journal of Immunology 163 (5), 2937-2943, 1999
Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects.
C Devito, J Hinkula, R Kaul, J Kimani, P Kiama, L Lopalco, C Barass, ...
Journal of acquired immune deficiency syndromes (1999) 30 (4), 413-420, 2002
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals
A Cosma, R Nagaraj, S Bühler, J Hinkula, DH Busch, G Sutter, FD Goebel, ...
Vaccine 22 (1), 21-29, 2003
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers
K Broliden, J Hinkula, C Devito, P Kiama, J Kimani, D Trabbatoni, ...
Immunology letters 79 (1-2), 29-36, 2001
Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
SA Calarota, AC Leandersson, G Bratt, J Hinkula, DM Klinman, ...
The Journal of Immunology 163 (4), 2330-2338, 1999
Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin
SE Applequist, E Rollman, MD Wareing, M Lidén, B Rozell, J Hinkula, ...
The Journal of Immunology 175 (6), 3882-3891, 2005
Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41
M Clerici, C Barassi, C Devito, C Pastori, S Piconi, D Trabattoni, R Longhi, ...
Aids 16 (13), 1731-1741, 2002
Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.
L Akerblom, J Hinkula, PA Broliden, B Mäkitalo, T Fridberger, J Rosen, ...
AIDS (London, England) 4 (10), 953-960, 1990
Humoral and cell‐mediated immune responses in humans to the NSP4 enterotoxin of rotavirus
K Johansen, J Hinkula, F Espinoza, M Levi, C Zeng, U Rudén, T Vesikari, ...
Journal of medical virology 59 (3), 369-377, 1999
Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.
J Hinkula, C Svanholm, S Schwartz, P Lundholm, M Brytting, G Engström, ...
Journal of virology 71 (7), 5528-5539, 1997
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery
A Bråve, K Ljungberg, A Boberg, E Rollman, M Isaguliants, B Lundgren, ...
Molecular Therapy 12 (6), 1197-1205, 2005
Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA
P Lundholm, Y Asakura, J Hinkula, E Lucht, B Wahren
Vaccine 17 (15-16), 2036-2042, 1999
A nonsense mutation (428G→ A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection
E Kindberg, B Hejdeman, G Bratt, B Wahren, B Lindblom, J Hinkula, ...
Aids 20 (5), 685-689, 2006
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics
VA Sundqvist, J Albert, E Ohlsson, J Hinkula, EM Fenyö, B Wahren
Journal of medical virology 29 (3), 170-175, 1989
Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA
AK Zuber, A Bråve, G Engström, B Zuber, K Ljungberg, M Fredriksson, ...
Vaccine 22 (13-14), 1791-1798, 2004
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen
B Mäkitalo, P Lundholm, J Hinkula, C Nilsson, K Karlen, A Mörner, ...
Journal of general virology 85 (8), 2407-2419, 2004
DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
L Buonaguro, C Devito, ML Tornesello, U Schröder, B Wahren, J Hinkula, ...
Vaccine 25 (32), 5968-5977, 2007
The system can't perform the operation now. Try again later.
Articles 1–20